By Lewis Krauskopf NEW YORK (Reuters) -Woes for U.S. healthcare stocks have worsened this year driven partly by Trump ...

Even though Bristol-Myers Squibb Company's ( NYSE:BMY ) recent earnings release was robust, the market didn't seem ...

US healthcare stocks struggle in 2025 due to government policies, sparking interest from bargain hunters as valuations reach ...

Patients with inflammatory bowel disease (IBD) have a 48% greater relative risk of developing interstitial lung disease (ILD) ...

Key Points On July 22, 2025, the U.S. Food and Drug Administration issued a Complete Response Letter for RP1, delaying potential commercialization and revenue. Research and development expenses ...

Key Points GAAP revenue surged to $66.8 million in Q2 2025, driven by recognition of one-time license and milestone payments, exceeding analyst estimates by 3,065.9% (GAAP). GAAP loss per share ...

Gilead Sciences generates stellar profit margins with its HIV and hepatitis C virus, or HCV, portfolio, which requires only a small salesforce and inexpensive manufacturing. We think its portfolio and ...

Detailed price information for Prime Medicine Inc (PRME-Q) from The Globe and Mail including charting and trades.

Flaws remain for office in the San Francisco Peninsula office — but demand is starting to improve, as net absorption was -406 ...

Novo Nordisk continues to deliver double-digit revenue and profit growth, driven by both its diabetes and obesity drug ...

News archive including articles on Fund Managers, Fund Selection, Asset Allocation, Absolute Return, Offshore Investments, Tax Shelters, Insurance bonds. Momentum returns as biotech enters next phase ...